The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of …

RIG Holt, JH DeVries, A Hess-Fischl, IB Hirsch… - Diabetes …, 2021 - Am Diabetes Assoc
The American Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD) convened a writing group to develop a consensus statement on the …

Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range

T Battelino, T Danne, RM Bergenstal, SA Amiel… - Diabetes …, 2019 - Am Diabetes Assoc
Improvements in sensor accuracy, greater convenience and ease of use, and expanding
reimbursement have led to growing adoption of continuous glucose monitoring (CGM) …

American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus

G Grunberger, J Sherr, M Allende, T Blevins, B Bode… - Endocrine practice, 2021 - Elsevier
Objective To provide evidence-based recommendations regarding the use of advanced
technology in the management of persons with diabetes mellitus to clinicians, diabetes-care …

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a …

C Mathieu, B Ásbjörnsdóttir, HS Bajaj, W Lane… - The Lancet, 2023 - thelancet.com
Background Insulin icodec (icodec) is a basal insulin analogue suitable for once-weekly
dosing. ONWARDS 4 aimed to assess the efficacy and safety of once-weekly icodec …

International consensus on use of continuous glucose monitoring

T Danne, R Nimri, T Battelino, RM Bergenstal… - Diabetes …, 2017 - Am Diabetes Assoc
Measurement of glycated hemoglobin (HbA1c) has been the traditional method for
assessing glycemic control. However, it does not reflect intra-and interday glycemic …

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a …

A Philis-Tsimikas, M Asong, E Franek, T Jia… - The Lancet Diabetes & …, 2023 - thelancet.com
Background Insulin icodec (icodec) is a once-weekly basal insulin currently under
development. ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec …

Validation of time in range as an outcome measure for diabetes clinical trials

RW Beck, RM Bergenstal, TD Riddlesworth… - Diabetes …, 2019 - Am Diabetes Assoc
OBJECTIVE This study evaluated the association of time in range (TIR) of 70–180 mg/dL
(3.9–10 mmol/L) with the development or progression of retinopathy and development of …

6. Glycemic Targets: Standards of Medical Care in Diabetes—2018

American Diabetes Association - Diabetes care, 2018 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
ADA's current clinical practice recommendations and is intended to provide the components …

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality …

SL Zheng, AJ Roddick, R Aghar-Jaffar, MJ Shun-Shin… - Jama, 2018 - jamanetwork.com
Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …

American D iabetes A ssociation S tandards of M edical C are in D iabetes 2017

PH Marathe, HX Gao, KL Close - 2017 - Wiley Online Library
The American Diabetes Association's (ADA) 2017 Standards of Care1 were published in
Diabetes Care on 15 December 2016. Notable changes in the new guidelines include the …